GlassScriptPhysician profile
Jonathan R Beers
NPI 1477783686
$2,673.75
in general payments reported to CMS, 2019-2025
29 companies · $14.23 in 2025
The $14.23 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $232 · 2021: $674 · 2022: $732 · 2024: $71.66 · 2025: $14.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $85.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $85.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $360.41 | 2019-2022 | |
| Amgen INC. | $338.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $298.74 | 2021-2022 | |
| Novo Nordisk INC | $254.15 | 2019-2022 | |
| Pfizer INC. | $240.42 | 2019-2022 | |
| Abbvie INC. | $132.59 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $120.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $107.91 | 2019-2022 | |
| Abbott Laboratories | $79.69 | 2021-2022 | |
| Grifols USA, LLC | $76.04 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.69 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $61.29 | 2021-2022 | |
| Eisai INC. | $58.38 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.98 | 2020-2022 | |
| Allergan, INC. | $48.85 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.59 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.37 | 2021-2022 | |
| Advanced Respiratory, INC | $38.16 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $35.89 | 2019 | |
| Philips North America LLC | $34.51 | 2019 | |
| Resmed Corp | $29.01 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.21 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $24.87 | 2019-2020 | |
| Apria Healthcare LLC | $22.89 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.23 | 2025 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.33 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.05 | 2022 | |
| Dexcom, INC. | $11.61 | 2021 | |
| Mylan Specialty L.P. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Beers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.